RA Capital

Ambros Therapeutics

ambrostherapeutics.com

Ambros Therapeutics, headquartered in Irvine, California, is a clinical-stage biotechnology company focused on the development of innovative and transformative medicines for diseases with a high unmet medical need. Our lead investigational program targets complex regional pain syndrome type 1 (CRPS-1), a devastating rare disease that causes severe, unrelenting and frequently lasting pain following trauma to the bone or an injury. Patients may experience significant functional loss, sleep disturbance, and meaningful diminished quality of life and independence. The Phase 3 pivotal trial (CRPS-RISE) represents a first-in-class approach to addressing a disease with no FDA-approved therapies.